Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were no more able than those on placebo to go three months without a red blood cell transfusion in a Phase 3 trial. There was a numerical and clinically meaningful improvement in transfusion independence favoring the product, which is intended to boost levels of a patient’s native red blood cells, BMS sa

Bengaluru: GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep , citing earlier concerns over side effects. The British drugmaker was trying to revive the drug, which was pulled from U.S. markets in 2022 after failing a late-stage study. Its shares fell as much as 7% to 1,315 pence by 0807 GMT, compared with a 0.2% rise in the FTSE 100 index. GSK's renewed application is base

Viatris said Friday its treatment candidate for a common form of eye inflammation failed a late-stage trial, casting uncertainty on the program’s future. The biotech’s pimecrolimus 0.3% ointment did not meet the Phase 3 primary endpoint of “complete resolution of debris” at six weeks versus vehicle, according to a release . The trial enrolled 477 patients with blepharitis, a condition that involves inflammation at the edges of the eyelids. Blepharitis causes swelling, itching and crusting of the

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a breakthrough in dental manufacturing, a new alopecia treatment and an app to help women navigate perimenopause. NEW YORK, July 18, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some

The impact of pharmaceutical tariffs would be "significant," Novartis CEO Vas Narasimhan said. The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff on pharmaceuticals.The long-threatened tariffs will arrive “probably at the end of the month,” the president suggested Tuesday. “We’re going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we’re going to make it a very

KIGALI, RWANDA — Emotions ran high this week at one of the world’s leading HIV science conferences after months of adapting in real-time to funding pullbacks that have shuttered or stalled critical HIV programs. The financial losses and uncertainty came up during many of the sessions at the International AIDS Society (IAS) Conference on HIV Science in the capital of Rwanda. But many attendees also expressed hope, as they’ve done for four decades of advancements and setbacks in HIV medicine, citi

New Delhi: The Fixed Dose Combination (FDC) of popular anti-diabetes medicine Metformin Hydrochloride and Voglibose is set to be excluded from the list of unapproved FDCs notified by the CDSCO in April this year. In a statement before the Delhi High Court over a petition challenging the classification of the combination as an unapproved drug, the Drugs Controller General of India ( DCGI ) has formally stated to exclude the above combination from the notified list. In April this year, the apex dr

Two PEG-based intermediates from BIOPHARMA PEG now listed in FDA DMF, supporting regulatory needs for drug delivery and bioconjugation. WATERTOWN, MA, UNITED STATES, July 18, 2025 / EINPresswire.com / -- BIOPHARMA PEG, a developer of functional polyethylene glycol (PEG) derivatives for pharmaceutical R&D, has announced that two of its PEG-based intermediates have been assigned Drug Master File (DMF) numbers by the U.S. Food and Drug Administration (FDA). The products now listed in the FDA's DMF

EQT X to acquire Adalvo, a rapidly growing, asset-light B2B dossier developer providing market-approval-ready generic drug dossiers to pharmaceutical companies EQT will support Adalvo's next phase of growth, further investing in R&D and innovation, and advancing the operational scale-up of the business Adalvo is uniquely positioned as a one-stop partner, combining strong business development capabilities with a flexible, customer-centric model to meet the bespoke needs of

XIAMEN, China, July 18, 2025 /PRNewswire/ -- Brain-Computer Interface (BCI) technology is redefining human-machine interaction by establishing direct communication between the brain and external devices. This transformative innovation is driving profound societal impact across industries: revolutionizing neurological disease treatment (e.g., epilepsy, Parkinson's, and depression), enhancing educational outcomes through improved focus, and enabling seamless industrial human-robot collaboration. W